Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database.

Poprach A, Bortlíček Z, Büchler T, Melichar B, Lakomý R, Vyzula R, Brabec P, Svoboda M, Dušek L, Gregor J.

Med Oncol. 2012 Dec;29(5):3314-20. doi: 10.1007/s12032-012-0286-9. Epub 2012 Jun 30.

PMID:
22752571
2.

Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry.

Kubackova K, Bortlicek Z, Pavlik T, Melichar B, Linke Z, Pokorna P, Vyzula R, Prausova J, Buchler T; Czech Renal Cancer Cooperative Group.

Target Oncol. 2015 Sep;10(3):385-92. doi: 10.1007/s11523-014-0343-8. Epub 2014 Oct 12.

PMID:
25304882
3.

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Chan HY, Grossman AB, Bukowski RM.

Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Epub 2010 Jul 8. Review.

PMID:
20623346
4.

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.

Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ.

BJU Int. 2011 Nov;108(10):1556-63. doi: 10.1111/j.1464-410X.2011.10629.x. Epub 2011 Sep 27. Review.

5.

Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients.

Shek D, Tomlinson B, Brown M, Brunson A, Pan CX, Lara PN Jr.

Clin Genitourin Cancer. 2012 Jun;10(2):93-8. doi: 10.1016/j.clgc.2012.01.007. Epub 2012 Feb 28.

PMID:
22382008
6.

Treatment of metastatic renal cell carcinoma.

Reeves DJ, Liu CY.

Cancer Chemother Pharmacol. 2009 Jun;64(1):11-25. doi: 10.1007/s00280-009-0983-z. Epub 2009 Apr 3. Review.

PMID:
19343348
7.

Pazopanib for the treatment of renal cancer.

Al-Marrawi MY, Rini B.

Expert Opin Pharmacother. 2011 May;12(7):1171-89. doi: 10.1517/14656566.2011.571206. Epub 2011 Apr 7. Review. Erratum in: Expert Opin Pharmacother. 2011 Jun;12(8):1349.

PMID:
21470066
8.

Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.

Porta C, Tortora G, Linassier C, Papazisis K, Awada A, Berthold D, Maroto JP, Powles T, De Santis M.

Med Oncol. 2012 Sep;29(3):1896-907. doi: 10.1007/s12032-011-0016-8. Epub 2011 Jul 7. Review.

PMID:
21735145
9.

Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.

Bukowski RM.

Expert Opin Pharmacother. 2010 Oct;11(14):2351-62. doi: 10.1517/14656566.2010.499126. Review.

PMID:
20586712
10.

Temsirolimus in renal cell carcinoma.

Otto T, Eimer C, Gerullis H.

Transplant Proc. 2008 Dec;40(10 Suppl):S36-9. doi: 10.1016/j.transproceed.2008.10.006.

PMID:
19100905
11.

A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.

Bellmunt J, Eisen T, Szczylik C, Mulders P, Porta C.

BJU Int. 2011 Apr;107(8):1190-9. doi: 10.1111/j.1464-410X.2010.09829.x. Epub 2010 Nov 15. Review.

12.

Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience.

Procopio G, Verzoni E, Iacovelli R, Guadalupi V, Gelsomino F, Buzzoni R.

Expert Rev Anticancer Ther. 2011 Nov;11(11):1631-40. doi: 10.1586/era.11.154. Review.

PMID:
22050012
13.

Pazopanib for the treatment of metastatic renal cell carcinoma.

Pick AM, Nystrom KK.

Clin Ther. 2012 Mar;34(3):511-20. doi: 10.1016/j.clinthera.2012.01.014. Epub 2012 Feb 16. Review.

PMID:
22341567
14.

Novel targets and therapies for metastatic renal cell carcinoma.

Feldman DR, Motzer RJ.

Oncology (Williston Park). 2006 Dec;20(14):1745-53; discussion 1756. Review.

15.

Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets.

MacLean E, Cisar L, Mehle K, Eremina D, Quigley JM.

J Manag Care Spec Pharm. 2016 Jun;22(6):723-732u. doi: 10.18553/jmcp.2016.22.6.723.

16.

Targeted therapy of renal cell cancer.

Wysocki PJ, Zolnierek J, Szczylik C, Mackiewicz A.

Curr Opin Investig Drugs. 2008 Jun;9(6):570-5. Review.

PMID:
18516756
17.

[Renal cell carcinoma: Drug therapy and prognostic models].

Reiter MA, Kurosch M, Haferkamp A.

Urologe A. 2015 May;54(5):735-46; quiz 747-8. doi: 10.1007/s00120-015-3845-9. German.

PMID:
25987339
18.

New treatment approaches in renal cell carcinoma.

Facchini G, Perri F, Caraglia M, Pisano C, Striano S, Marra L, Fiore F, Aprea P, Pignata S, Iaffaioli RV.

Anticancer Drugs. 2009 Nov;20(10):893-900. doi: 10.1097/CAD.0b013e32833123d4. Review.

PMID:
19752718
19.

[Second-line treatment of advanced renal cell carcinoma after first-line targeted therapy].

Tomita Y.

Gan To Kagaku Ryoho. 2011 Jun;38(6):907-10. Japanese.

PMID:
21677480
20.

Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma.

Yang CH, Chuang CK, Hsieh JJ, Chang JW.

Expert Opin Drug Saf. 2010 May;9(3):459-70. doi: 10.1517/14740331003596349. Review.

PMID:
20113155

Supplemental Content

Support Center